Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Responses closed . Full description on SAM.gov.
Description
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed:
a. Adquey - Atopic - Subclass: Topical Agents
b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims
c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma
d. Bixlenvo - Antiretrovirals - Subclass: Combinations
e. Clotic - Antifungals - Subclass: NA
f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist
g. Langlara - Insulins - Subclass: Basal
h. Lisraya - Targeted Immunomodulatory Biologics – NA
i. Mimrylo - Hematological Agents – NA
j. Nuzolvence - Antibiotics – NA
k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors
l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404.
Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Overview
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (16)
- Download
A-3 RFQ HT9402-26-Q-9404 NAD.pdf
983 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Adquey-Atopic-Topical Agents.xlsx
57 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Armlupeg-White Blood Cell Stim-Pegfilgrastims.xlsx
49 KBAdded in Solicitation version 1Posted - Download
A-3 Price List - Beqalzi - Onc Agents - Non-BTKI CLL-SLP.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Bixlenvo-Antiretrovirals-Combinations.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Clotic-Antifungals-NA.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Etcamah-Breast Canc Agt-Estrogen Recptr Antag.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Langlara-Insulins-Basal.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Lisraya - TIBs - NA.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List - Mimrylo - Hematological Agents - NA.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List - Nuzolvence -Antibiotics - NA.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List_Rasonque-Oncological Agents-RAS Inhibitors.xlsx
45 KBAdded in Solicitation version 1Posted - Download
A-3 Price List - Rezenopy - Alcohol Deterrents-Narcotic Antag.xlsx
45 KBAdded in Solicitation version 1Posted - Download
FAR 52-225-6-Certificate.pdf
645 KBAdded in Solicitation version 1Posted - Download
Price Appendix FAQ NAD.pdf
231 KBAdded in Solicitation version 1Posted - Download
DoD Formulary Placement of FDA Newly Approved Drugs.pdf
83 KBAdded in Solicitation version 1Posted
Links (1)
- https://health.mil/PandThealth.milPosted
Lifecycle
- 1Version 1SolicitationCurrent
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following August 2026 drug classes/subclasses will be reviewed: a. ADHD Agents – Stimulants AZSTARYS COTEMPLA XR-ODT DYANAVEL XR JORNAY PM MYDAYIS QUILLICHEW ER QUILLIVANT XR XELSTRYM b. Oncological Agents - BRAF-MEK Inhibitors BRAFTOVI COTELLIC MEKINIST MEKTOVI TAFINLAR ZELBORAF The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9301. Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | Solicitation | 325412 | No Set-Aside | 05/07/2026 | 06/29/2026 | San Antonio, TX | |
NOTICE OF INTENT TO SOLE SOURCE: The Defense Health Agency – Healthcare Contracting Division – South, intends to award a sole source contract in accordance with RFO FAR 8.104 (Use of Existing Contracts) to INO THERAPEUTICS LLC, to procure delivery of Inhaled Nitric Oxide (iNO) for use at the Department of Medicine. at Brooke Army Medical Center, Fort Sam Houston, Texas. The period of performance is 01 JAN 2027 – 31 DEC 2027, plus four (4) option years. This notice serves to announce the Government’s intent to sole source this requirement and determine if any other sources exist. Interested sources with the demonstrated capability to meet all of the technical requirements outlined in this notice are invited to submit, in writing. Responses must include clear and convincing evidence that competition would be beneficial to the Government and would not be cost or schedule prohibitive. Respondents are responsible for appropriately marking any proprietary information. Responses will not be returned. The contractor shall deliver the following crucial elements: (a) the supply of nitric oxide for inhalation, the pharmaceutical drug essential for the therapy (800 parts per million [PPM]); (b) a specialized Delivery Device that meets the precise criteria outlined in the iNO product label for safe and effective administration, (c) all necessary maintenance and calibration items, accessories, and disposable supplies required for the ongoing operation of the system, and (d) a range of support services, including training, maintenance, pick-up and delivery logistics. This synopsis/notice of intent to sole source is issued in accordance with Federal Acquisition Regulation (FAR) Revolutionary FAR Overhaul (RFO) 5.101 and 12.102 and will be posted for 15 days. Response Due Date: October 22, 2026 by 12:00 PM (CST) Submit to: Contracting Officer: Joe D. Wells at joe.d.wells3.civ@health.mil. . | Market Research | 325412 | No Set-Aside | 10/08/2026 | 10/22/2026 | 0, TX | |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | Solicitation | 325412 | No Set-Aside | 08/06/2026 | 10/01/2026 | - | |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | Solicitation | 325412 | No Set-Aside | 08/06/2026 | 08/27/2026 | San Antonio, TX | |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following August 2026 newly approved drugs will be reviewed: a. Atoncy – ADHD Agents – Subclass: Non-stimulants b. Baxfendy – Diuretics – Subclass: Mineralocorticoid Receptor Antagonists c. Duloxetine - Antidepressants And Non-opioid Pain Syndrome Agents – Subclass: SNRI d. Filkri – White Blood Cell Stimulants – Subclass: Filgrastims (Only ADP eligible due to non-TAA compliance) e. Hepcludex – Hepatitis D Agent – Subclass: NA f. Lynavoy – Gastrointestinal-2 Agents – Subclass: NA g. Veppanu - Breast Cancer Agents – Subclass: Estrogen Receptor Antagonist h. Xocova – Antivirals – Subclass: FDA Approved COVID Therapeutics i. Xtoro - Antibiotics – Subclass: Quinolones The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9304. Pre-quotation teleconference is on July 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2. | Solicitation | 325412 | No Set-Aside | 07/16/2026 | 07/27/2026 | - |
Additional Details
Solicitation Number
HT9402-26-Q-9404
Archive Date
Apr 26, 2027
Office Address
JBSA FT SAM HOUSTON, TX, 78234